Adults with type 2 diabetes using a GLP-1 receptor agonist have a similar risk for developing thyroid cancer as those using a ...

In a large population of people with diabetes, the use of GLP-1 receptor agonists was not linked to an increased risk for ...

TNF Pharmaceuticals, Inc. (Nasdaq: TNFA) ("TNFA" or the "Company"), a clinical stage biopharmaceutical company committed to ...

A nationwide study confirms GLP-1 RAs pose no short-term psychiatric risk, showing a negative association with suicidal ...

The following is a summary of “Association between incretin-based drugs and risk of cholangiocarcinoma among patients with ...

Mounjaro is a GLP-1 inhibitor developed to help people with diabetes regulate their blood glucose. Elon Musk, the 53-year-old CEO of Tesla and SpaceX, recently shared a festive image of himself ...

Elon Musk/X Mounjaro, like Ozempic, is a GLP-1 inhibitor – a class of drugs developed to help people with diabetes regulate their blood glucose and insulin levels. However, Americans have ...

In previous First Word columns, I discussed the effects of SGLT2 inhibitors on the kidney to prevent progression of chronic ...

Not long after the FDA wrapped its preliminary investigation of GLP-1 receptor agonists and suicidal thoughts or actions, the ...

With the holidays past and the new year arrived, we look ahead — to losing weight. For some that resolve theoretically ...

A lean-looking Elon Musk revealed Wednesday that he uses Mounjaro — after previously expressing support for similar weight-loss drugs as a means to curb America’s obesity epidemic. The ...

Alongside the photo, Musk revealed that he uses Mounjaro, a GLP-1 inhibitor, instead of Ozempic, citing its fewer side effects and greater effectiveness In a festive spirit, Elon Musk, the 53-year ...